Abstract 125P
Background
Bevacizumab biosimilar (Avegra®) became available for patients in Russia since 2015. Since introduction, no real-world data except clinical cases was available. We decided to assess the safety and effectiveness of Avegra® in patients treated in daily practice according to national treatment protocols. Depending on the geography the study was divided into Apollon-11, conducted in Moscow, and Soyuz-Apollon, conducted in 18 regions of Russia. The final analysis summarizes pooled results of all regions.
Methods
This multicentre prospective observational post-authorization study of bevacizumab biosimilar combined with chemotherapy in patients with metastatic colorectal cancer was conducted in 28 centres in Russia from December 2019 to January 2023. Patients with metastatic colorectal cancer (mCRC), treated with bevacizumab at a dose of 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with standard chemotherapy regimens as a first line of therapy were included. Primary safety endpoints were the incidence of adverse reactions (ARs) related to bevacizumab and the rate of treatment discontinuation due to ARs.
Results
438 patients with mCRC in 28 research centres of the Russian Federation were included in the study. Median age of patients was 62 (28–87) years, ECOG performance status of £1. Most of the tumors were left-sided (67.8%) and had at least one RAS/BRAF mutation (55.9%). After median follow-up of 7.3 months, adverse reactions occurred in 11%, of which 2.7% were grade ³3. Treatment was discontinued in 2.8% of patients due to adverse reactions. Objective response was achieved in 37.9% of patients (95% CI 31.4 - 41.6) with 2.8% of complete responses. Median progression-free survival was 9.4 months (95% CI 8.1 - 10.7). Median overall survival was not reached.
Conclusions
Our findings are consistent with previously known bevacizumab safety and efficacy profile. Numerically low incidence of ARs is most likely due to reduced reporting of adverse events in real-world clinical practice settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BIOCAD.
Funding
BIOCAD.
Disclosure
A. Tryakin, M. Fedyanin, F.V. Moiseenko: Financial Interests, Personal, Coordinating PI: BIOCAD. M. Mariam, O. Mironov, D. Stroyakovskiy, N. Sokolov, S. Orlova, E. Mantsyrev, A.V. Sultanbaev, A. Teterich, K. Babina, D. Yukalchuk, S. Borzyanitsa, A. Isyangulova, A. Saidullaeva, I. Chernova, E. Bobrova, N. Fadeeva: Financial Interests, Personal, Local PI: BIOCAD.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract